Table 2.
Baseline characteristics of HCV-uninfected, previously exposed and chronically infected participants
| Factor | At risk of naive infection (n = 95) | At risk of reinfection (n = 139) | Not at risk: AB+, RNA+ (n = 217) |
|---|---|---|---|
| Age (years), mean (s.d.) | 27·7 (4·6) | 29·7 (5·0) | 30·1 (4·8) |
| Male gender, n (%) | 65 (68·4) | 72 (54·9) | 151 (69·6) |
| Injecting career (years), mean (s.d.) | 7·9 (5·1) | 11·4 (5·6) | 11·3 (5·0) |
| Needle-sharing past month, n (%) | 3 (3·2) | 19 (14·7) | 34 (16·0) |
| Injecting at least daily, n (%) | 49 (51·6) | 81 (58·7) | 139 (64·5) |
| Current opioid substitution therapy, n (%) | 36 (37·9) | 66 (47·5) | 91 (41·9) |
Some variables have missing data.